Fondaparinux labels and packages: Difference between revisions

Revision as of 00:13, 6 February 2014

Fondaparinux
Arixtra^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fondaparinux
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Adapted from the FDA Package Insert.

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AZ}}
-<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate =  }}</ref>
+==Labels And Packages==
+{|
+|[[File:Fondaparinux 2.5 mg.JPG|600px|thumb]]
+|}
+{|
+|[[File:Fondaparinux 5 mg.JPG|600px|thumb]]
+|}
+{|
+|[[File:Fondaparinux 7.5 mg.JPG|600px|thumb]]
+|}
+{|
+|[[File:Fondaparinux 10 mg.JPG|600px|thumb]]
+|}<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate =  }}</ref>
 ==References==